Giovanni Crotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giovanni Crotti has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Nottegar
Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, University of Verona, Verona, Italy
12 shared publications - Claudia Orrù
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
12 shared publications - Cristina Migliore
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
12 shared publications - Daniela Conticelli
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
12 shared publications - Dinçer Kılıç
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
12 shared publications - Erika Calabrò
Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
12 shared publications
Latest Publications
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
H‐score correlation between the pathologists for AREG, EREG, and HER3 biomarkers.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
H‐score correlation between the pathologists for AREG, EREG, and HER3 biomarkers.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of the expression of EGFR and HER2 in cetuximab sensitive vs resistant cells.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of the expression of EGFR and HER2 in cetuximab sensitive vs resistant cells.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Overall survival according HER3 expression in the COG cohort.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Overall survival according HER3 expression in the COG cohort.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of apoptosis and cell cycle upon cetuximab treatment.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of apoptosis and cell cycle upon cetuximab treatment.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Cross‐sensitivity of GEA primary cells among EGFR targeting drugs.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Cross‐sensitivity of GEA primary cells among EGFR targeting drugs.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Overall survival according AREG or EREG overexpression in ACRG cohort.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Overall survival according AREG or EREG overexpression in ACRG cohort.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
AREG and EREG RNAscope staining and quantification.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
AREG and EREG RNAscope staining and quantification.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of EGFR ligands in cetuximab sensitive vs resistant PDX models.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of EGFR ligands in cetuximab sensitive vs resistant PDX models.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of EGFR pathway activation.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Evaluation of EGFR pathway activation.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Features of the analyzed models.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Features of the analyzed models.